MedTrace Logo

Safety And Efficacy Of Empagliflozin In Pakistani Muslim Population With Type Ii Diabetes Mellitus

NCT04665284 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 244

Last updated 2020-12-11

No results posted yet for this study

Summary

To compare the safety and efficacy of empagliflozin versus other treatments in Pakistani Muslim population with type II diabetes mellitus.

Conditions

  • Type II Diabetes Mellitus

Interventions

DRUG

Empagliflozin

Group A: Empagliflozin 10/25 mg once daily with or without antidiabetic drugs

DRUG

Usual care group

Group B: usual care group but without Empagliflozin with adjustment of therapy as the standard of care

Sponsors & Collaborators

  • Getz Pharma

    lead INDUSTRY

Principal Investigators

  • A H Aamir · Post Graduate Medical Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-06-01
Primary Completion
2020-09-15
Completion
2020-09-28

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04665284 on ClinicalTrials.gov